Literature DB >> 15836699

Causes of increased mortality from hepatocellular carcinoma in high incidence country: Taiwan experience.

Chyi-Feng Jan1, Chien-Jen Chen, Hsiu-Hsi Chen.   

Abstract

BACKGROUND: Since 1991, a rapid rise in mortality from hepatocellular carcinoma (HCC) has been observed in Taiwan in subjects aged >/=20 years. The aim of the present study was to assess whether poor survival or excess incident cases pertaining to a cohort effect or a time-period effect accounted for such a rise.
METHODS: A total of 41 150 deaths and 51 201 incident HCC patients (International Classification of Diseases = 155.0) aged 20-79 years between 1985 and 1998 were studied. Trends in HCC mortality rates were divided into two groups: annual case-fatality rates and HCC incidence rates by age. Poisson regression was used to distinguish a cohort effect from a time-period effect on the incidence of HCC.
RESULTS: Subjects aged >50 years after 1991 had the greatest risk of death (relative risk [RR] = 11.3; 95% confidence interval [CI]: 11.0-11.7). Annual case-fatality rates declined from 1.6 in 1985 to 0.84 in 1998, whereas there was a remarkable increase in incidence, particularly from 1991 onward, in the >50-year-olds. It was found that subjects aged >50 years who were born before 1944 were the group most susceptible to HCC (RR = 9.3; 95%CI: 9.1-9.5).
CONCLUSION: Increased incidence, particularly in individuals over 50, rather than poor survival, accounts for the rapid rise in mortality from HCC. (c) 2004 Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2005        PMID: 15836699     DOI: 10.1111/j.1440-1746.2005.03602.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  4 in total

1.  Unexpected remission of hepatocellular carcinoma (HCC) with lung metastasis to the combination therapy of thalidomide and cyproheptadine: report of two cases and a preliminary HCC cell line study.

Authors:  Yu-Min Feng; Chin-Wen Feng; Solomon Chih-Cheng Chen; Cheng-Da Hsu
Journal:  BMJ Case Rep       Date:  2012-10-12

2.  Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening.

Authors:  Ming-Jeng Kuo; Hsiu-Hsi Chen; Chi-Ling Chen; Jean Ching-Yuan Fann; Sam Li-Sheng Chen; Sherry Yueh-Hsia Chiu; Yu-Min Lin; Chao-Sheng Liao; Hung-Chuen Chang; Yueh-Shih Lin; Amy Ming-Fang Yen
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

3.  Factors affecting prognosis of small hepatocellular carcinoma in Taiwanese patients following hepatic resection.

Authors:  Chih-Jan Ko; Su-Yu Chien; Chen-Te Chou; Li-Sheng Chen; Mei-Ling Chen; Yao-Li Chen
Journal:  Can J Gastroenterol       Date:  2011-09       Impact factor: 3.522

4.  Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase.

Authors:  Yu-Min Feng; Chin-Wen Feng; Syue-Yi Chen; Hsiao-Yen Hsieh; Yu-Hsin Chen; Cheng-Da Hsu
Journal:  BMC Cancer       Date:  2015-03-17       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.